Rapid Detection of the GSTM3 A/B Polymorphism Using Real-time PCR with TaqMan® Probes  by Martínez-Treviño, Denisse A. et al.
Archives of Medical Research 47 (2016) 142e145PRELIMINARY REPORT
Rapid Detection of the GSTM3 A/B Polymorphism Using Real-time
PCR with TaqMan Probes
Denisse A. Martınez-Trevi~no,a Marıa G. Moreno-Trevi~no,a Mauricio Salinas-Santander,b
Luisa Wohn,a Sarahı Herrera-Gonzalez,a Marcelino Aguirre-Garza,a O. Carolina Rojas,a and
Rafael B.R. Leon-Cachona
aDepartamento de Ciencias Basicas, Universidad de Monterrey, Division Ciencias de la Salud, San Pedro Garza Garcıa, Nuevo Leon, Mexico
bFacultad de Medicina, Unidad Saltillo, Universidad Autonoma de Coahuila, Saltillo, Coahuila, Mexico
Received for publication December 11, 2015; accepted April 6, 2016 (ARCMED-D-15-00867).Address reprint re
Monterrey, Ave. Igna
Monterrey, 66238, M
(81) 8215-1447; E-m
0188-4409/Copyright
licenses/by-nc-nd/4.0/
http://dx.doi.org/10Glutathione S-transferases (GSTs) are a group of phase II detoxification enzymes, which
catalyze the conjugation of glutathione (GSH) with carcinogens, among other xenobi-
otics. The GSTM3 gene is part of the GSTs gene family, and its polymorphism A/B
has been associated with risk and protective effects of several cancers. This genetic
variant is a deletion of 3 bp (AGG) in intron 6. Previous association studies have per-
formed genotyping using techniques such as polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP). In this study, we took advantage of the
TaqMan probes features and developed a reliable, faster, more simple and economic
method to identify the 3-bp deletion. Our allelic discrimination method was able to distin-
guish between homozygous A/A, heterozygous A/B and homozygous B/B samples, as
shown by TaqMan based real-time PCR. Results were validated by Sanger Sequencing.
In conclusion, we developed a specific and rapid method to detect the 3-bp deletion from
the GSTM3 A/B polymorphism.
 2016 IMSS. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Polymorphism.Introduction
Glutathione S-transferases GSTs are included in the group
of phase II detoxification enzymes, which catalyze the
conjugation of glutathione (GSH) of a variety of com-
pounds including carcinogens and therapeutic drugs (1).
Several cytosolic and polymorphic families of GST have
been identified such as alpha (GSTA), mu (GSTM), omega
(GSTO), pi (GSTP), theta (GSTT) and zeta (GSTZ) (2). In
particular, in the GSTM3 gene, two alleles have been
described, the wild-type GSTM3 A and the variant GSTM3
B (3). The latter possess a 3-bp deletion (AGG) in intron 6,
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).
.1016/j.arcmed.2016.04.002factor Ying Yang (YY1) 5-AAGATA-30 (3). Therefore, this
deletion could alter the expression of GSTM3, possibly also
affecting carcinogen metabolism and cancer susceptibility
(4). Controversial results have been previously reported
regarding the association of GSTM3 polymorphisms and
the risk or protective effects in different types of cancer
and populations. For instance, both GSTM3 A/B and B/B
genotypes have been associated with increased risk of
laryngeal cancer in Caucasian populations (5). The same
genotypes showed enhanced risk for developing esophageal
cancer in a Northern Indian population (4). Conversely,
increased risks of oral cancer and leukoplakia were
observed in tobacco smokers with the GSTM3 A/A geno-
type in an Indian population (6). Other studies have tested
association between GSTM3 A/B polymorphism and breast
cancer risk (in a population from northeastern Mexico) (7)
and lung cancer susceptibility (in a meta-analysis) (8).
Neither of these showed an association. Because thecess article under the CC BY-NC-ND license (http://creativecommons.org/
143GSTM3 A/B Polymorphism Detected by TaqMan Probesidentification of this polymorphism has been widely per-
formed with polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) (3,9e11), we sought to
design an alternative, reliable and specific method that al-
lows determination of the deletion in a simpler and faster
way. This method will be a very useful tool for those
who wish to analyze the GSTM3 A/B polymorphism in
future studies.Material and Methods
Origin of DNA Samples
In order to validate our method, human genomic DNA sam-
ples were required. Therefore, experiments were carried out
with DNA from 56 healthy volunteers from the Universidad
de Monterrey who initially participated in a study to iden-
tify obesity-associated biomarkers in the mitochondrial
DNA (12). The study complied with the guidelines of the
Declarations of Helsinki and Tokyo and was approved by
the Research and Ethics Committee from the Universidad
de Monterrey (registration number 322012-ClE). The
DNA sample with the homozygous genotype GSTM3 B/B
was obtained from a student in the Universidad de Monter-
rey with Venezuelan ancestry. Informed consent from all
participants was obtained.
DNA Extraction
Peripheral blood from the 56 participants was extracted in a
tube with EDTA and genomic DNA was isolated with
Wizard Genomic DNA Purification Kit (Promega, Madison,
WI). Protocol was followed according to manufacturer’s in-
structions. Genomic DNAwas quantified by UVabsorbance
using Nanodrop (Thermo Scientific, Wilmington, DE). The
quality of DNA was measured with the A260/280 ratio; a
value of 1.8e2 was considered of good quality. All samples
were adjusted to a concentration of 10 ng/ml and distributed
in a 96-well plate. Samples were kept at 20C until
analysis.
Design of the TaqMan Allelic Discrimination Method
A costumed TaqMan genotyping assay was ordered with
Applied Biosystems (Foster City, CA). First, the 3-bp
deletion was identified in the GSTM3 gene sequence.
The gene sequence was then entered in the File Builder
3.1 software (Applied Biosystems) and the deletion site
marked. A file was created and sent to the manufacturer.
The allelic discrimination design consisted of oligonucle-
otides and two labeled probes, which included the wild-
type probe labeled with VIC dye (A allele) and the variant
probe labeled with FAM dye (B allele, lacking the 3 bp).
The passive reference dye included in the assay tube was
ROX. Real-time PCR reaction was performed according tothe manufacturer’s instructions in an ABI PRISM 7000
Sequence Detection System (Applied Biosystems). Briefly,
the reaction was set with an input DNA of 20 ng, 1X
probe and oligonucleotides mix, 1X TaqMan Universal
PCR Master Mix (Applied Biosystems) and nuclease-
free water to a total volume of 11 ml. Probes and oligonu-
cleotides sequences are available upon request. Thermal
cycling conditions were as following: 60C for 30 sec,
95C for 10 min, 40 cycles of: 95C for 15 sec and
60C for 1 min. A final post-read method was set at
60C for 30 sec.
Sequencing Reactions
In order to validate the TaqMan allelic discrimination
method, samples were prepared for sequencing. First,
end-point PCR was carried out with Go-taq flexi DNA po-
lymerase (Promega) in an Eppendorf Mastercycle EP
gradient S Thermal (Eppendorf, Hamburg, Germany).
Briefly, 200 ng of DNA were amplified by adding 1X
buffer, 1.5 mmol MgCl2, 0.2 mmol dNTPs, 0.2 mM of each
primer and 1.25 U/reaction DNA polymerase in a total vol-
ume of 50 ml. The amplification program included an initial
denaturation step of 94C for 3 min followed by 30 cycles
of: denaturation at 94C for 30 sec, annealing at 56C for
40 and extension: 72C for 1 min, a final extension step
was set at 72C for 5 min. Purification of PCR products
was performed with QIAquick (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. Samples were
sequenced in a Genetic Analyzer 3100 (Applied Bio-
systems) by an external supplier, the Instituto Potosino de
Investigacion Cientıfica y Tecnologica (IPICYT, SLP,
Mexico). Sequences were analyzed with the CodonCode
Aligner software.Results
TaqMan Allelic Discrimination Method
Samples from the 56 participants were run in the ABI
PRISM 7000 Sequence Detection System. The total pro-
cedure lasted 3 h, from preparing the PCR reaction to the
analysis of the results. Two genotypes were initially identi-
fied in these samples (GSTM3 A/A and GSTM3 A/B), with a
frequency of 88.33 and 11.67%, respectively. In the 56 sam-
ples, no GSTM3 B/B genotype was found. These results
were expected becausee frequency of B/B genotype is ab-
sent or very low in the northeastern Mexican population
(0e4%) (7,13).
In order to validate the detection of the homozygous B/B
genotype by the TaqMan probe, we sought a DNA sample
that possesses this genotype. Homozygous B/B genotype
has been found to be more frequent in sub-Saharan African
populations (56e58%) and moderately frequent in Cauca-
sians (5e20%) (11). Therefore, we invited students from
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donate DNA. A total of eight students decided to participate
and, surprisingly, one possessed the B/B genotype. Ancestry
of this student was documented to be from Venezuela (par-
ents from Venezuela, grandparents from Colombia, Peru
and Venezuela, great-grandparents from Italy, Venezuela,
Colombia and Peru). TaqMan allelic discrimination was
then performed with this sample plus samples previously
classified as GSTM3 A/A or GSTM3 A/B and the allelic
discrimination plot was observed clearly with three clusters
(Figure 1). Amplification data proved the specificity of the
method because fluorescence was detected only for one sin-
gle allele in homozygous samples and for both alleles in
heterozygous samples. Threshold cycle (Ct) values ranged
from 26.72 to 29.66. In order to assess the sensitivity of
our method, the test was performed with different concen-
trations of input DNA (15, 10, 5 and 2.5 ng per reaction).
Allelic discrimination plot was clearly observed with
three clusters for all the diluted samples. Amplification data
of the assay carried out with 2.5 ng showed Ct values
ranged from 29.0e30.23. These results confirm the high
sensitivity of our proposed TaqMan allelic discrimination
method.
Validation of the TaqMan Allelic Discrimination Method
with Sanger Sequencing
In order to validate the results obtained with the TaqMan
allelic discrimination assay, one sample of each phenotype
was prepared for sequencing. Sequence analysis showed the
absence of the 3 bp in the homozygous B/B sample, the
presence of the 3 bp in the homozygous A/A and the com-
bination of both alleles was identified in the sequence of the
heterozygous A/B sample (Figure 2).Figure 1. Detection of the GSTM3 A/B polymorphism by real-time PCR using T
representing a different genotype, red circles: homozygous GSTM3 A/A, green tria
homozygous GSTM3 B/B genotype. Gray squares: negative controls. The axis v
(FAM for the B allele and VIC for the A allele). Fluorescence was read at the eDiscussion
In recent years, the features of the TaqMan probes have
been considered for the detection of mutations and poly-
morphisms associated with several diseases such as cancer
(14), dystrophic epidermolysis bullosa (15), beta thalas-
semia (16), among others. In this study, the 3-bp deletion
in the GSTM3 gene was identified by our TaqMan allelic
discrimination method. The real-time PCR procedure takes
an approximate time of 3 h until results are observed in the
allelic discrimination plot. The estimated cost of each sam-
ple is |$2.5e3 USD. This method is faster, more economic
and simpler compared with the regular PCR-RFLP proce-
dure currently used to detect this polymorphism. Results
showed high specificity because fluorescence was detected
whether for one allele in homozygous samples and for both
in heterozygous samples.
The current method most commonly used in the scienti-
fic community to detect the GSTM A/B polymorphism is
PCR-RFLP, which allows determining the presence or
absence of the 3-bp deletion in the GSTM3 gene through
the use of conventional end-point PCR and restriction en-
zymes. Therefore, this technique requires sufficient amount
of DNA, 50e100 ng per PCR reaction (10), whereas our
TaqMan allelic discrimination method can be carried out
only with 2.5 ng. Additionally, the time required to perform
PCR-RFLP can be very extensive because various tech-
niques need to be done: PCR for |2 h, digestion that is nor-
mally performed overnight or for 18 h (3,10),
polyacrylamide gel preparation stained with ethidium bro-
mide and run of the gel for 2 h (3). TaqMan allelic
discrimination method allows performing the determination
in 2e3 h. Toxicity of polyacrylamide and ethidium bro-
mide, besides the risk of contamination between samplesaqMan probes. The allelic discrimination plot shows three groups, each
ngles: heterozygous GSTM3 A/B and the blue square is the sample with the
alues represent the relative fluorescence (DRn) between both probes dyes
nd of the run as a post-read method.
Figure 2. Nucleotide sequences of samples possessing one of the three
GSTM3 genotypes in intron 6. (A) Sequence of a sample with homozygous
GSTM3 A/A genotype showing the presence of the AGG bp. (B) Sample
with heterozygous GSTM3 A/B genotype, showing both alleles, allele A
(upper sequence) and allele B showing the deletion of the AGG bp (lower
sequence). (C) Sequence of the sample with B/B genotype, lacking the
AGG bp. Electropherograms were obtained from the CodonCode Aligner
software.
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the PCR-RFLP method that are overcome by using Taq-
Man probes.
Therefore, this TaqMan allelic discrimination method
will allow the development of more GSTM3 association
studies in a faster, more specific, sensitive and economic
way when comparing to the currently used method (PCR-
RFLP).Conclusion
A new method based on real-time PCR using TaqMan
probes has been designed, tested, and proven to be rapid,
specific and sensitive for the detection of the GSTM3 A/B
polymorphism.Acknowledgments
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